Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

被引：0
|
作者：
Muggia, F. M. [1 ,2 ]
Boyd, L. [1 ,2 ]
Liebes, L. [1 ,2 ]
Downey, A. [1 ,2 ]
Muller, C. [1 ,2 ]
Pothuri, B. [1 ,2 ]
Blank, S. [1 ,2 ]
Rutledge, T. [1 ,2 ]
Fishman, D. [1 ,2 ]
Verschraegen, C. [1 ,2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5548
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Four years of experience with combined weekly non-pegylated liposomal doxorubicin and taxane in breast cancer second-line treatment
    Rosati, M. S.
    Basile, M. L.
    Sacco, P. C.
    Cerbone, L.
    Pasciutti, G.
    Falbo, T.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2007, 18 : 49 - 49
  • [22] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer.
    Caron, Whitney Paige
    Lay, John C.
    Kumar, Parag
    Fong, Alan M.
    La-Beck, Ninh My
    Newman, Suzanne E.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Linda Van Le
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin plus pegylated liposomal doxorubicin in second line
    Colombo, Nicoletta
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 : 13 - 17
  • [24] Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older
    Vergote, I.
    Vermorken, J.
    Pujade-Lauraine, E.
    Monk, B.
    Lisyanskaya, A.
    Rolski, J.
    Vasanthan, S.
    Santabarbara, P.
    Bayever, E.
    Poveda, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 458 - 458
  • [25] Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma - A retrospective study
    Di Lorenzo, Giuseppe
    Di Trolio, Rossella
    Montesarchio, Vincenzo
    Palmieri, Giovanna
    Nappa, Paola
    Delfino, Mario
    De Placido, Sabino
    Dezube, Bruce J.
    CANCER, 2008, 112 (05) : 1147 - 1152
  • [26] Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
    Xin-Ru Li
    Xing-Han Cheng
    Guo-Nan Zhang
    Xiao-Xin Wang
    Jian-Ming Huang
    Journal of Ovarian Research, 15
  • [27] Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
    Li, Xin-Ru
    Cheng, Xing-Han
    Zhang, Guo-Nan
    Wang, Xiao-Xin
    Huang, Jian-Ming
    JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)
  • [28] Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
    Rubio Perez, M. J.
    Manzano Fernandez, A.
    De Sande Gonzalez, L. M.
    Estevez Garcia, P.
    Gordon Santiago, M. D. M.
    Soto De Prado, D.
    Hernando Fernandez, B. A.
    Guerra Alia, E. M.
    Carbo Bague, A.
    Romero, I.
    Corbellas Aparicio, M.
    Gonzalez-Haba Martinez, A.
    Robles Barraza, C. E.
    Martinez-Garcia, J.
    Gonzalez Martin, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S523 - S523
  • [29] Interleukin-12 gene therapy in combination with bevacizumab and pegylated liposomal doxorubicin for treatment of disseminated ovarian cancer
    Fewell, Jason G.
    Matar, Majed M.
    Rice, Jennifer
    McClure, Diane
    Brunhoeber, Elaine
    Sparks, Jeff
    Greenleaf, Stefanie
    Smith, Kelley
    Anwer, Khursheed
    CANCER RESEARCH, 2016, 76
  • [30] Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer
    Todorovic, Vladimir
    Saric, Nada Cicmil
    Lakicevic, Jadranka
    Sorat, Milan
    JOURNAL OF BUON, 2017, 22 (05): : 1131 - 1136
12345